-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Cytokinetics, Raises Price Target to $96

Benzinga·02/25/2026 12:24:04
Listen to the news
Citizens analyst Jason Butler maintains Cytokinetics (NASDAQ:CYTK) with a Market Outperform and raises the price target from $88 to $96.